{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:20:00Z","timestamp":1777047600714,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21Y11909000"],"award-info":[{"award-number":["21Y11909000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202140518"],"award-info":[{"award-number":["202140518"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Peripheral T\u2010cell lymphomas (PTCL) frequently result in relapsed or refractory diseases. Upfront autologous hematopoietic stem cell transplantation (ASCT) using the BEAM (carmustine, etoposide, cytarabine, and melphalan) regimen is recommended. However, relapses are common in PTCL, highlighting a critical need for improved survival outcomes in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Anthracycline drugs are essential in treating PTCL. We compared the efficacy and tolerability of a high\u2010dose mitoxantrone\u2010based conditioning regimen [mitoxantrone, cyclophosphamide, and etoposide (MCE)] to the BEAM regimen in upfront ASCT for newly diagnosed PTCL patients who achieved complete or partial remission after induction therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design<\/jats:title><jats:p>A retrospective study was conducted to analyze the treatment response, progression\u2010free survival (PFS), overall survival (OS), hematologic engraftment time, and adverse events of 64 patients between two regimens, who achieved complete or partial remission after induction chemotherapy. Twenty\u2010eight patients received the MCE regimen, while 36 patients were treated with the BEAM regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no significant differences in clinical characteristics or the incidence of adverse events between the two groups. However, the median OS significantly favored the MCE group at 102.4 (95% CI, 87.0\u2013117.8) months compared to 62.6 (95% CI, 50.8\u201374.5) months in the BEAM group (<jats:italic>p<\/jats:italic>\u2009=\u20090.023). Similarly, the median PFS was longer in the MCE group at 87.8 (95% CI, 65.8\u2013109.8) months versus 42.5 (95% CI, 30.0\u201355.0) months in the BEAM group (<jats:italic>p<\/jats:italic>\u2009=\u20090.031).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ASCT with the mitoxantrone\u2010based conditioning regimen is tolerable and appears to significantly improve the prognosis of PTCL patients, offering a promising alternative to the current standard of care.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70476","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:48:21Z","timestamp":1733748501000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mitoxantrone\u2010Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T\u2010Cell Lymphoma Compared to <scp>BEAM<\/scp> Regimen"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-288X","authenticated-orcid":false,"given":"Xinyu","family":"Zuo","sequence":"first","affiliation":[{"name":"Department of Hematology, Huadong Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-0003","authenticated-orcid":false,"given":"Wensi","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huadong Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huadong Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huadong Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiexian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huadong Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128172"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0524"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00892-4"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0734-7"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0382-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351924"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6965"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0196-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.04.002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00892"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2022.12.001"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18540-x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27291"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001575"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702154"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.005"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01766-8"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_10_22_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5","author":"National Institutes of Health, National Cancer Institute","year":"2017"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14477"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0360-9"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05416-x"},{"issue":"19","key":"e_1_2_10_26_1","first-page":"2646","article-title":"A Randomized Phase 3 Trial of Autologous vs Allogeneic Transplantation as Part of First\u2010Line Therapy in Poor\u2010Risk Peripheral T\u2010NHL","volume":"137","author":"Schmitz N.","year":"2021","journal-title":"Blood"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705744"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17829"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.05.016"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147093"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-133487","article-title":"Synergistic Antitumor Effect and Mechanism of Chidamide Combined With Gemcitabine, Oxaliplatin or Zanubrutinib in Diffuse Large B\u2010Cell Lymphoma","volume":"136","author":"Cai Q.","year":"2020","journal-title":"Blood"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:54:06Z","timestamp":1739958846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/cam4.70476"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70476","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70476"}}